Conference
Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.
Abstract
252
Background: The management of patients with mCRPC has evolved since the introduction of androgen-receptor axis targeted agents (ARATs). The Genitourinary Research Consortium (GURC) initiated a prospective, phase 4, multicentre, non-interventional, longitudinal cohort study of Canadian men with advanced prostate cancer to determine real-world treatment patterns and outcomes. Methods: 25 sites across Canada participated in …
Authors
Lavallee L; Morash C; Saad F; Yip S; Kapoor A; Kolinsky MP; Pouliot F; Antebi E; Drachenberg D; Ferrario C
Volume
40
Pagination
pp. 252-252
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2022
DOI
10.1200/jco.2022.40.6_suppl.252
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X